Tags

Type your tag names separated by a space and hit enter

Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.
Expert Rev Pharmacoecon Outcomes Res. 2012 Aug; 12(4):439-41.ER

Abstract

BACKGROUND

Multiple sclerosis (MS) is a chronic, progressive disease that carries a high socioeconomic burden. Spasticity (rigidity and spasms) is common in MS and a key contributor to MS-related disability.

OBJECTIVES

This study evaluated the cost-effectiveness of Sativex®, a 9-d-tetrahydrocannabinol/cannabidiol-based oromucosal spray that acts as an endocannabinoid system modulator. Sativex was recently approved for the management of resistant MS spasticity as add-on medication.

METHODS

A Markov model-based analysis was performed over a 5-year horizon from a German and Spanish healthcare payer perspective. The incremental cost of Sativex was low compared with current spasticity treatments, and provided a quality-adjusted life-year gain over the current standard of care.

RESULTS

The base-case incremental cost-effectiveness ratio for Sativex was estimated at €11,214/quality-adjusted life-year in Germany, while the drug was the dominant option in Spain, providing savings of €3496/patient over a 5-year period (year of costing: 2010). This was seen because the lower severity of spasticity in patients who had improved led to reduced resource consumption (e.g., physiotherapy and medications).

CONCLUSION

Despite having a relatively high acquisition cost, Sativex was shown to be a cost-effective treatment option for patients with MS-related spasticity.

Authors+Show Affiliations

Universitat Autònoma de Barcelona, Campus de la UAB, Bellaterra, Spain.No affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

22681512

Citation

Slof, John, and Adrien Gras. "Sativex® in Multiple Sclerosis Spasticity: a Cost-effectiveness Model." Expert Review of Pharmacoeconomics & Outcomes Research, vol. 12, no. 4, 2012, pp. 439-41.
Slof J, Gras A. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):439-41.
Slof, J., & Gras, A. (2012). Sativex® in multiple sclerosis spasticity: a cost-effectiveness model. Expert Review of Pharmacoeconomics & Outcomes Research, 12(4), 439-41. https://doi.org/10.1586/erp.12.40
Slof J, Gras A. Sativex® in Multiple Sclerosis Spasticity: a Cost-effectiveness Model. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):439-41. PubMed PMID: 22681512.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sativex® in multiple sclerosis spasticity: a cost-effectiveness model. AU - Slof,John, AU - Gras,Adrien, Y1 - 2012/06/08/ PY - 2012/6/12/entrez PY - 2012/6/12/pubmed PY - 2013/2/5/medline SP - 439 EP - 41 JF - Expert review of pharmacoeconomics & outcomes research JO - Expert Rev Pharmacoecon Outcomes Res VL - 12 IS - 4 N2 - BACKGROUND: Multiple sclerosis (MS) is a chronic, progressive disease that carries a high socioeconomic burden. Spasticity (rigidity and spasms) is common in MS and a key contributor to MS-related disability. OBJECTIVES: This study evaluated the cost-effectiveness of Sativex®, a 9-d-tetrahydrocannabinol/cannabidiol-based oromucosal spray that acts as an endocannabinoid system modulator. Sativex was recently approved for the management of resistant MS spasticity as add-on medication. METHODS: A Markov model-based analysis was performed over a 5-year horizon from a German and Spanish healthcare payer perspective. The incremental cost of Sativex was low compared with current spasticity treatments, and provided a quality-adjusted life-year gain over the current standard of care. RESULTS: The base-case incremental cost-effectiveness ratio for Sativex was estimated at €11,214/quality-adjusted life-year in Germany, while the drug was the dominant option in Spain, providing savings of €3496/patient over a 5-year period (year of costing: 2010). This was seen because the lower severity of spasticity in patients who had improved led to reduced resource consumption (e.g., physiotherapy and medications). CONCLUSION: Despite having a relatively high acquisition cost, Sativex was shown to be a cost-effective treatment option for patients with MS-related spasticity. SN - 1744-8379 UR - https://www.unboundmedicine.com/medline/citation/22681512/Sativex®_in_multiple_sclerosis_spasticity:_a_cost_effectiveness_model_ L2 - http://www.tandfonline.com/doi/full/10.1586/erp.12.40 DB - PRIME DP - Unbound Medicine ER -